Capvizr
News · All summaries
Healthcare & Life Sciences
Enveda
Series E$311 million
2 disclosed rounds
RoundSeries E
Amount$311 million
LeadCatalio Capital Management</strong>
DateSeptember 23, 2026
THE DEAL, AT A GLANCE

Enveda

From the announcement
Who is involvedBacked by Catalio Capital Management</strong>, bringing its, Iconiq, natural chemistryFrom the announcement

Summarized from the deal record's source announcement; not yet independently reviewed.

Read the announcement ↗
What happenedEnveda raised $311M Series E, announced 2026-09-23From the announcement

Summarized from the deal record's source announcement; not yet independently reviewed.

Read the announcement ↗
Why it mattersEnveda’s $311 million Series E supports a platform thesis that AI-discovered natural medicines can produce clinic-ready and later-stage drug programs, with Catalio…From the announcement

Summarized from the deal record's source announcement; not yet independently reviewed.

Read the announcement ↗
Click a part to explore its evidence. Unsupported imagery is withheld rather than guessed.Original record source ↗

Enveda · Financing Record

Explore source-linked visual explanations for Enveda. Unsupported claims are withheld while source review continues.

Record 12671 · Recorded date: 2026-09-23

Explore company records →
Free weekday briefing

Know which funding rounds matter before the first call.

Source-linked rounds, lead investors, and the signal behind the capital. One five-minute read.

Free · Unsubscribe anytime